Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

The Blunders of In Re Kubin

A recent U.S. Federal Circuit of Appeals decision (In Re Kubin) distorts the definition of a patentable invention, threatening the future of biotechnology innovation in the United States. Read our summary.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

BIO IP News Weekly for March 20, 2009

BIO’s weekly newsletter of stories compiled from a variety of public news sources, previously only available to BIO members, is now publicly available: See our temporary version here to check out the news we’re following for March 20, 2009.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

US Court of Appeals for the Federal Circuit Issues Decision in Tafas v Dudas

Read the Decision here: http://tinyurl.com/ce6o7r Read BIO’s Comments to the US Patent and Trademark Office on Proposed Rule Changes Concerning Claims Containing Alternative Language: http://www.bio.org/ip/domestic/20071009.pdf

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Monsanto Company: “Protect Innovation”

Read Monsanto Company’s guest blog post on innovation and patent reform on Patently-O Blog.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

HHS Requests Public Comment on Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests

HHS Requests Public Comment on Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests.

Patently BIOtech  |  Leave a comment  |  Email This Post